Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

MR Stockler; AJ Martin; H Dhillon; ID Davis; KN Chi; S Chowdhury; LG Horvath; NJ Lawrence; GM Marx; J Mc Caffrey; R McDermott; SA North; F Parnis; DW Pook; MN Reaume; SK Sandhu; TH Tan; A Thomson; R Zielinski; CJ Sweeney

Conference Proceedings

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

MR Stockler, AJ Martin, H Dhillon, ID Davis, KN Chi, S Chowdhury, LG Horvath, NJ Lawrence, GM Marx, J Mc Caffrey, R McDermott, SA North, F Parnis, DW Pook, MN Reaume, SK Sandhu, TH Tan, A Thomson, R Zielinski, CJ Sweeney

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

DOI: 10.1093/annonc/mdz394.046

Abstract

Background We previously reported that treatment with enzalutamide (ENZA) rather than an older non-steroidal anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide), resulted in longer overall survival when added to standard first-line treatment, with or without concurrent early docetaxel, in mHSPC (hazard ratio 0.67, 95% CI 0.52 to 0.86, p=0.002, NEJM 2019). Here we report effects on HRQL. Methods HRQL was measured with the EORTC QLQ-C30 and PR25 at weeks 0, 4, 12, and then 12-weekly until clinical progression. We used mixed models for repeated measures to calculate the least squares mean difference (LSMD), 95% CI, and p-value for comparisons of the randomly assigned groups for all ass..

View full abstract